Phase 3
N=240
AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
Conjunctivitis, Allergic
Bottom Line
View on ClinicalTrials.gov: NCT02161146 ↗Enrolled (actual)
240
Serious AEs
0.0%
Results posted
Mar 2016
Primary outcome: Primary: Ocular Itching Score — 0.33; 1.48; 0.29 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- AGN-229666 (Drug); Vehicle to AGN-229666 (Drug); Olopatadine (Drug)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Allergan
- Primary completion
- Dec 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Ocular Itching Score |
0.33; 1.48; 0.29 | — |
| SECONDARY Conjunctival Hyperemia Score |
1.15; 1.61; 1.34 | — |
Summary
This study will evaluate the safety and efficacy of AGN-229666 for the prevention of allergen-mediated conjunctivitis.
Eligibility Criteria
Inclusion Criteria
-Japanese patients living in Japan with a history of allergic conjunctivitis.
Exclusion Criteria
- Presence of active eye infection (bacterial, viral, or fungal)
- History of an eye herpetic infection.
Data sourced from ClinicalTrials.gov (NCT02161146). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.